title: Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells.
abstract: The observation that depletion or inhibition of regulatory T cells (Tregs) unleashes efficient antitumor effector immune responses that can lead to tumor eradication in mice has opened new perspectives for the development of cancer immunotherapy. The quality and overall efficiency of the effector immune responses induced in the absence of Tregs seem to depend on multiple factors that determine the result of a battle involving effector T cells (Teffs), Tregs and tumor cells. In this study, we investigated the quality of tumor-associated antigens (TAAs) as one such factor. We show that the presence of a strong dominant antigen is required for the induction of effector responses capable of tumor eradication in the absence of Tregs. The sole addition of a dominant antigen on tumor cells does not change tumor growth in unmanipulated mice, but improves tumor eradication rate from a few to almost 100% in the absence of Tregs. This eradication can be shown to result from the recruitment and activation of specific Teffs recognizing this antigen. We also show that the presence of such dominant antigens has the side effect of restricting the breadth of the immune response to other TAAs, which could favor the generation of escape mutant by tumor editing. Taken together, our results highlight the potential, and some requirements for cancer immunotherapy based on Treg depletion. They also show that, ultimately, tumor fate depends on multiple factors that should all be taken into consideration for the design of more efficient immunotherapy.
authors.affiliation: UPMC Univ Paris 06, UMR 7211, Immunology-Immunopathology-Immunotherapy (I3), Paris, France.
authors.forename: A-S
authors.initials: AS
authors.lastname: Bergot
authors.forename: A
authors.initials: A
authors.lastname: Durgeau
authors.forename: B
authors.initials: B
authors.lastname: Levacher
authors.forename: B M
authors.initials: BM
authors.lastname: Colombo
authors.forename: J L
authors.initials: JL
authors.lastname: Cohen
authors.forename: D
authors.initials: D
authors.lastname: Klatzmann
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D015153:Blotting, Western; D005260:Female; D005434:Flow Cytometry; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000378:metabolism; D007167:Immunotherapy; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology; D015674:Mammary Neoplasms, Animal / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008654:Mesothelioma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D000951:Antigens, Neoplasm; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D012333:RNA, Messenger
references.citation: Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103
references.pmid: 9223321
references.citation: Nat Immunol. 2002 Nov;3(11):999-1005
references.pmid: 12407407
references.citation: J Exp Med. 2005 Oct 3;202(7):885-91
references.pmid: 16186187
references.citation: Immunol Rev. 1998 Aug;164:111-8
references.pmid: 9795769
references.citation: Nat Immunol. 2007 Apr;8(4):351-8
references.pmid: 17322887
references.citation: Nat Rev Cancer. 2008 Apr;8(4):299-308
references.pmid: 18354418
references.citation: Nature. 1988 Nov 24;336(6197):388-90
references.pmid: 3264053
references.citation: J Immunol. 2006 Jun 1;176(11):6434-42
references.pmid: 16709800
references.citation: J Immunol. 2002 Nov 15;169(10):5796-804
references.pmid: 12421960
references.citation: Nature. 2001 May 17;411(6835):380-4
references.pmid: 11357146
references.citation: Int J Oncol. 2009 Sep;35(3):569-81
references.pmid: 19639177
references.citation: Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81
references.pmid: 10500201
references.citation: Science. 2008 Jan 11;319(5860):215-20
references.pmid: 18187659
references.citation: Nat Rev Immunol. 2007 Aug;7(8):645-50
references.pmid: 17641664
references.citation: Int J Oncol. 2006 Feb;28(2):519-25
references.pmid: 16391808
references.citation: J Immunol. 2007 Oct 15;179(8):4969-78
references.pmid: 17911581
references.citation: J Immunother. 2002 May-Jun;25(3):207-17
references.pmid: 12000862
references.citation: J Exp Med. 1994 Jul 1;180(1):347-52
references.pmid: 7516411
references.citation: Nat Med. 2004 Sep;10(9):909-15
references.pmid: 15340416
references.citation: J Immunother. 2004 May-Jun;27(3):184-90
references.pmid: 15076135
references.citation: Eur J Immunol. 1999 Oct;29(10):3295-301
references.pmid: 10540341
references.citation: J Immunol. 1999 Nov 15;163(10):5211-8
references.pmid: 10553041
references.citation: Immunity. 2007 Aug;27(2):203-13
references.pmid: 17707129
references.citation: Eur J Immunol. 2003 Feb;33(2):556-66
references.pmid: 12645955
references.citation: Nat Rev Cancer. 2003 Sep;3(9):666-75
references.pmid: 12951585
references.citation: Nat Med. 2007 Apr;13(4):423-31
references.pmid: 17384649
references.citation: Cell. 1987 Apr 24;49(2):273-80
references.pmid: 3494522
references.citation: J Exp Med. 2001 Sep 17;194(6):823-32
references.pmid: 11560997
references.citation: Int J Cancer. 1992 Dec 2;52(6):881-6
references.pmid: 1459729
references.citation: Int Immunol. 2001 May;13(5):625-32
references.pmid: 11312250
references.citation: J Exp Med. 2002 Mar 4;195(5):657-64
references.pmid: 11877489
references.citation: J Immunol. 1999 May 15;162(10):5838-45
references.pmid: 10229818
references.citation: J Autoimmun. 2004 Mar;22(2):111-4
references.pmid: 14987738
references.citation: Cancer. 2007 Dec 15;110(12):2614-27
references.pmid: 18000991
references.citation: J Clin Invest. 2009 Sep;119(9):2648-62
references.pmid: 19652360
references.citation: J Exp Med. 1994 Jul 1;180(1):25-34
references.pmid: 8006585
references.citation: J Immunol. 2006 Aug 15;177(4):2167-74
references.pmid: 16887976
references.citation: J Immunol. 2000 Jun 1;164(11):5641-51
references.pmid: 10820239
references.citation: Annu Rev Immunol. 1993;11:729-66
references.pmid: 7682817
references.citation: Br J Cancer. 2010 Jan 5;102(1):124-33
references.pmid: 19953093
references.citation: Science. 1991 Dec 13;254(5038):1643-7
references.pmid: 1840703
references.citation: Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6707-11
references.pmid: 8022837
references.citation: Cancer Res. 1999 Jul 1;59(13):3128-33
references.pmid: 10397255
references.citation: J Exp Med. 1995 Jul 1;182(1):75-85
references.pmid: 7540658
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19954-9
references.pmid: 18042727
references.citation: J Immunol. 2000 Jun 1;164(11):5782-7
references.pmid: 10820256
references.citation: J Virol. 2002 Jan;76(2):767-73
references.pmid: 11752166
references.citation: J Immunol. 2005 Nov 1;175(9):6169-76
references.pmid: 16237114
references.citation: Cancer Res. 2003 Dec 15;63(24):9007-15
references.pmid: 14695219
references.citation: J Exp Med. 2002 Sep 16;196(6):851-7
references.pmid: 12235217
references.citation: J Immunol. 2002 May 1;168(9):4391-8
references.pmid: 11970981
references.citation: Nature. 2005 Sep 1;437(7055):141-6
references.pmid: 16136144
references.citation: Science. 1996 Mar 22;271(5256):1734-6
references.pmid: 8596936